• Ovid outlined a pipeline targeting neural hyperexcitability, led by OV329, a next-generation GABA-aminotransferase inhibitor for drug-resistant focal onset seizures.
• OV329 Phase 2 randomized controlled trial initiated, with topline results targeted for mid-2027; an open-label photo-paroxysmal response study also started.
• Proof-of-concept safety and signal-finding studies in tuberous sclerosis complex seizures and infantile spasms planned to start in Q4 2026.
• Phase 1 data cited strong tolerability at 7 mg, no treatment-related serious adverse events, no ophthalmic safety findings; once-daily dosing, no titration expected.
• Ovid also advanced OV4071, an oral KCC2 direct activator, with Phase 1 proof-of-mechanism ongoing; ketamine challenge study slated for H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.